US biotech Regenxbio (Nasdaq: RGNX) has entered a definitive deal to acquire Dimension Therapeutics (Nasdaq: DMTX) in an all-stock transaction for an implied value of about $3.41 per share.
This values the transaction at around $86 million, and the offer price is nearly three times that of Dimension’s closing price of $1.20 ahead of the announcement, which caused the company’s shares to skyrocket 160% as an instant reaction. The boards of directors of both companies have unanimously approved the transaction.
On completion of the acquisition, Regenxbio will add two lead product candidates to its pipeline:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze